U.S. Central Venous Catheter Market Overview, Opportunities, Demands And Growth Analysis Till 2026

Central
venous catheters consist of a long, thin tube that is
inserted into a large vein to deliver medication, nutrition,
intravenous fluids, and cancer medications. Different types of
central venous catheters can be utilized by patients according to the
duration of the treatment. These include, tunneled central venous
catheters (CVC) and implanted ports for long term use, peripherally
inserted central catheter (PICC) for intermediate term, and
non-tunneled CVC for short term use. Central venous catheterization
is used for chemotherapy administration, total parenteral nutrition,
administration of intravenous fluids and blood, platelet
transfusions, and other applications.
Market Dynamics
Increasing
prevalence of renal diseases is a major factor driving the central
venous catheter market growth. According to the National Center for
Chronic Disease Prevention and Health Promotion, 2017, around 30
million people or 15% of the U.S. adults were estimated to have
chronic kidney.
Moreover,
introduction of innovative products and increasing requirement of
long-duration IV therapies such as chemotherapy is expected to boost
the market growth. For instance, in May, 2018, Pursuit Vascular,
Inc., received the U.S. Food and Drug Administration (FDA) clearance
for a broader indication of its ClearGuard HD caps to include
reduction in the incidence of central-line associated bloodstream
infection (CLABSI) in hemodialysis patients with central venous
catheters (CVCs).
Increasing
prevalence of cancer is expected to propel growth of the central
venous catheter market
Cancer is a class of
chronic disease that is characterized by out-of-controlled growth of
cells. According to The National Cancer Institute, 2013, there are
over 100 different types of cancer that can be described from the
type of cells they are formed from. According to the American Cancer
Society, 2017, cancer is the second most common cause of death in the
U.S., which accounts for nearly 1 out of every 4 deaths.
Ask For Discount
Before Purchasing This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/2610
According to the
National Center for Chronic Disease Prevention and Health Promotion,
2017, around 30 million people or 15% of the U.S. adults were
estimated to have chronic kidney.
According to the
World Health Organization (WHO), 2012, cancer is the second leading
cause of morbidity and mortality worldwide, with around 14 million
new cases registered in 2012. Furthermore, WHO stated that the number
of new cases is expected to increase by around 70% by 2030. In 2015,
cancer was responsible for 8.8 million deaths worldwide.
Increasing
collaboration strategies adopted by market players is expected to
bolster growth of the U.S. central venous catheter market
The U.S. central
venous catheter market is expected to witness significant growth due
to increasing adoption of collaboration strategies by market players.
For instance, in 2017, Becton, Dickinson, and Company acquired C.R.
Bard, Inc. which created a new health care industry leader with
approximately US$ 16 billion in annualized revenue. Similarly, in
July 2018, B.Braun Melsungen AG acquired the bloodlines business of
NxStage Medical, Inc. This acquisition helped dialysis business of B.
Braun Melsungen AG.
Key Players
Major players
operating in the U.S. central venous catheter market include,
AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B.
Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc.,
Argon Medical Devices, Inc., ICU Medical, Inc., and Theragenics
Corporation.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment